FCM
IONS icon

Fourpath Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Fourpath Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,049
Closed -$42K – 499
2024
Q3 		$42K Buy
+1,049
New +$48.8K 0.01% 357

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Fourpath Capital Management's IONS Position: Q4 2024 in Review

Fourpath Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2024, closing a stake of 1,049 shares — an estimated $42K sold.

Fourpath Capital Management first reported a position in IONS in Q3 2024 and held it in 1 quarter. The position peaked at $42K in Q3 2024. 354 funds tracked by Wall St. Rank hold IONS as of Q4 2024.

  • Fourpath Capital Management reported no remaining Ionis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Fourpath Capital Management sold 1,049 Ionis Pharmaceuticals shares in Q4 2024, an estimated $42K.
  • Fourpath Capital Management first reported a position in Ionis Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Fourpath Capital Management's Ionis Pharmaceuticals position peaked at $42K in Q3 2024.
  • 354 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2024.

Based on Fourpath Capital Management's 13F filing for Q4 2024, filed 24 Jan 2025.